生命科学资讯

'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership

United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial

From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot

Lisata reclaims China rights to solid tumor candidate ahead of acquisition

After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

Virtual women’s health company Wisp buys TBD Health

Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere

Jan Nolta: UC Davis Partners with Thermo Fisher to Expand Access to Advanced Therapies - Oncodaily

Thermo Fisher Scientific Inc. $TMO Position Reduced by Ownership Capital B.V. - MarketBeat

A potential gene therapy for heart failure is an approach decades in the making

Maresin 1 improves cardiac function after myocardial infarction

University of Sydney discloses coagulation factor XIa inhibitors

University of Kansas identifies TNF-α/HuR interaction inhibitors

Korean researchers discover new HBV PreS1 derivatives

Thermo Fisher's Niton XL5e: Precision in Elemental Analysis - AZoMining

Leerink Partners lowers 10X Genomics stock price target on pricing concerns - Investing.com

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech